Addressing One of Healthcare’s Largest Problems
The rapid emergence of resistant bacteria is endangering the efficacy of antibiotics, thus causing a serious threat to global health care.
Each year in the US alone, at least 2 million people become infected with drug-resistant bacteria, and 23,000 people die as a direct result.
ArcDia’s mariAST® is the most promising diagnostic platform to tackle antibiotic resistance. It is rapid, easy-to-use and cost-effective. mariAST allows near-patient analysis directly from clinical samples without isolation of the bacteria strain.
ArcDia’s mariAST® is based on ArcDia’s mariPOC® field-proven test system. The mariPOC® product line for multianalyte testing of acute infections covers viruses and bacteria for the most common respiratory infections and for gastroenteritis.
NEWS
mariPOC® ensures lower probability for C. difficile misdiagnosis with precision
mariPOC® ensures lower probability for C. difficile misdiagnosis with precision mariPOC® CDI test is a…
New research data shows that influenza antigen testing correlates best with the infectivity period
ArcDia Scientific Feed New research data shows that influenza antigen testing correlates best with the…
13th – 16th April 2019 ECCMID, Amsterdam, Netherlands
See you in Amsterdam, ECCMID 2019. Information about the posters to be announced later.
Read more →26th – 27th of September Life Sciences Baltics, Vilnius, Lithuania
R&D Director of ArcDia, Dr. Janne Koskinen is giving presentation in Life Sciences Baltics conference.…
Read more →“The automated test system mariPOC® enables the detection of 8 respiratory viruses in 2 hours with minimal sample processing and covers viruses for which there are little or no other rapid antigen test available.”